The advisory agreement aims to strengthen Antibiotice's capacity to attract financing, support future investments and reinforce long-term competitiveness in a rapidly evolving healthcare market. The EIB support will also reinforce transparency, operational oversight and long-term sustainability across the company's activities.
Antibiotice, which is headquartered in Iași in northeastern Romania, provides over 200 products for human and veterinary use and employs over 1,300 employees. Promoting the company's competitiveness and growth prospects through stronger governance will also boost economic development and job creation in Romania.
"Ensuring companies like Antibiotice are equipped for long-term investment means better and patient-oriented healthcare, more jobs and a stronger economy," said EIB Vice-President Ioannis Tsakiris. "This partnership reflects our commitment to helping key industries modernise, attract investment and contribute to Romania's sustainable growth through InvestEU."
"This partnership with the EIB represents an important step in strengthening our long-term strategic development," said Antibiotice's General Director Ioan Nani. "The expertise and support provided will help us further align with international industry standards, create foundations for new investments and support long-term development."
